Clinical Trial Update: Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating befotertinib plus bevacizumab or platinum-based chemotherapy for resectable locally-advanced EGFR-mutant non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: Peng Zhang | Conditions: EGFR, Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING